MULTI-OMICS ANALYSIS OF PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH ANTI-PD-L1 PLUS ANTI-CTLA-4 AND LOCOREGIONAL THERAPY: CORRELATIVE STUDY OF PHASE2 TRIAL

被引：0
|
作者：
Myojin, Yuta [1 ]
Babei, Sepideh [2 ]
Hoffman, Christoph [2 ]
Kedei, Noemi [1 ]
Ruf, Benjamin [1 ]
Benmebarek, Mohamed-Reda [1 ]
Bauer, Kylynda [1 ]
Huang, Patrick [1 ]
Trehan, Rajiv [1 ]
Ma, Chi [1 ]
Monge, Cecilia [1 ]
Xie, Changqing [1 ]
Armstrong, Paul [3 ]
Duffy, Austin [3 ]
Korangy, Firouzeh [1 ]
Claassen, Manfred [2 ]
Greten, Tim [1 ]
机构：
[1] Natl Canc Inst, Bethesda, MD USA
[2] Univ Tubingen, Tubingen, Germany
[3] Mater Misericordiae Univ Hosp, Dublin, Ireland
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1815
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Immune cell dynamics of patients and mice with hepatocellular carcinoma treated with anti-PD-L1 plus anti-CTLA-4 combination therapy
    Myojin, Yuta
    Ruf, Benjamin
    Benmebarek, Mohamed-Reda
    Bauer, Kylynda
    Trehan, Rajiv
    Coffman, Kelley
    Ma, Chi
    Monge, Cecilia B.
    Xie, Changqing
    Greten, Tim
    CANCER RESEARCH, 2023, 83 (07)
  • [2] Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
    Su, Xin
    Li, Jian
    Xu, Xiao
    Ye, Youbao
    Wang, Cailiu
    Pang, Guanglong
    Liu, Wenxiu
    Liu, Ang
    Zhao, Changchun
    Hao, Xiangyong
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [3] Effect of cancer vaccine formulation on synergy with anti-CTLA-4 and anti-PD-L1 checkpoint blockade therapy of cancer
    Hailemichael, Yared
    Fu, Tihui
    Woods, Amber
    Schluns, Kimberly
    Engelhard, Victor H.
    Sharma, Padmanee
    Overwijk, Willem W.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies
    Kudo, Masatoshi
    LIVER CANCER, 2019, 8 (06) : 413 - 426
  • [5] The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
    Xu, Da
    Wang, Hongwei
    Bao, Quan
    Jin, Kemin
    Liu, Ming
    Liu, Wei
    Yan, Xiaoluan
    Wang, Lijun
    Zhang, Yanqiao
    Wang, Guangyu
    Ma, Yue
    Ma, Zhigang
    Zhang, Chunhui
    Tang, Jiebing
    Wang, Sha
    Pang, Jiaohui
    Xu, Ting
    Wang, Kun
    Xing, Baocai
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [6] High tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L+NSCLC patients (pts) treated with anti-PD-L1 and anti-CTLA-4
    Higgs, B. W.
    Morehouse, C. A.
    Brohawn, P. Z.
    Sridhar, S.
    Raja, R.
    Gao, G.
    Englert, J.
    Ranade, K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4+Anti-PD-1 Therapy
    Buchbinder, Elizabeth. I. I.
    Pfaff, Kathleen. L. L.
    Turner, Madison. M. M.
    Manos, Michael
    Ouyang, Olivia
    Ott, Patrick. A. A.
    Giobbie-Hurder, Anita
    Rodig, Scott. J. J.
    Hodi, F. Stephen
    JOURNAL OF IMMUNOTHERAPY, 2023, 46 (05) : 192 - 196
  • [8] A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies
    J. Nehra
    P. A. Bradbury
    P. M. Ellis
    J. Laskin
    C. Kollmannsberger
    D. Hao
    R. A. Juergens
    G. Goss
    P. Wheatley-Price
    S. J. Hotte
    K. Gelmon
    A. V. Tinker
    P. Brown-Walker
    I. Gauthier
    D. Tu
    X. Song
    A. Khan
    Lesley Seymour
    M. Smoragiewicz
    Investigational New Drugs, 2020, 38 : 1442 - 1447
  • [9] A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies
    Nehra, J.
    Bradbury, P. A.
    Ellis, P. M.
    Laskin, J.
    Kollmannsberger, C.
    Hao, D.
    Juergens, R. A.
    Goss, G.
    Wheatley-Price, P.
    Hotte, S. J.
    Gelmon, K.
    Tinker, A. V.
    Brown-Walker, P.
    Gauthier, I.
    Tu, D.
    Song, X.
    Khan, A.
    Seymour, Lesley
    Smoragiewicz, M.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1442 - 1447
  • [10] Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy
    Schaberg, Kurt B.
    Novoa, Roberto A.
    Wakelee, Heather A.
    Kim, Jinah
    Cheung, Christine
    Srinivas, Sandhya
    Kwong, Bernice Y.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2016, 43 (04) : 339 - 346
12345